• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by BioAge Labs Inc.

    3/24/26 4:07:46 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BIOA alert in real time by email
    S-8 1 bioa-20260324.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on March 24, 2026

    Registration No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER THE
    SECURITIES ACT OF 1933

     

    BIOAGE LABS, INC.

    (Exact name of Registrant as specified in its charter)

     

    Delaware

    47-4721157

    (State or other jurisdiction of
    incorporation or organization)

    (I.R.S. Employer
    Identification Number)

    5885 Hollis Street, Suite 370

    Emeryville, California 94608

    (510) 806-1445

    (Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

    2024 Equity Incentive Plan

    2024 Employee Stock Purchase Plan

    (Full title of the plans)

    Kristen Fortney, Ph.D.

    Chief Executive Officer and President

    BioAge Labs, Inc.

    5885 Hollis Street, Suite 370

    Emeryville, California 94608

    (510) 806-1445

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Please send copies of all communications to:

    Matthew Rossiter, Esq.

    Robert A. Freedman, Esq.

    Julia Forbess, Esq.

    Fenwick & West LLP

    One Front Street

    33rd Floor

    San Francisco, California 94111

    (415) 875-2300

     


     

     

    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definition of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    ☐

     

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

     

    Smaller reporting company

    ☒

     

     

     

    Emerging growth company

    ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

    Registration of Additional Shares
    Pursuant to General Instruction E

    BioAge Labs, Inc. (the “Registrant”) is filing this Registration Statement with the Securities and Exchange Commission (the “Commission”) to register (a) 1,869,345 additional shares of the Registrant’s common stock available for issuance under the Registrant’s 2024 Equity Incentive Plan (the “2024 EIP”) pursuant to the provision of the 2024 EIP providing for an annual 5% automatic increase in the number of shares reserved for issuance under the 2024 EIP, and (b) 373,869 additional shares of the Registrant’s common stock available for issuance under the Registrant’s 2024 Employee Stock Purchase Plan (the “2024 ESPP”) pursuant to the provision of the 2024 ESPP providing for an annual 1% automatic increase in the number of shares reserved for issuance under the 2024 ESPP.

    In accordance with General Instruction E of Form S-8, and only with respect to the common stock issuable under the 2024 EIP and 2024 ESPP, this Registration Statement hereby incorporates by reference the contents of the Registrant’s Registration Statements on Form S-8 filed with the Commission on September 26, 2024 (Registration No. 333-282352) and March 20, 2025 (Registration No. 333-285980) to the extent not superseded hereby.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference

    The following documents filed by the Registrant with the Commission pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”) are incorporated herein by reference:

    (a)
    the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Commission on March 24, 2026, pursuant to Section 13(a) of the Exchange Act;
    (b)
    all other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrants Annual Report on Form 10-K referred to in (a) above; and
    (c)
    the description of the Registrant’s common stock contained in the Registrant’s registration statement on Form 8-A (File No.001-42279) filed on September 18, 2024, under Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description.

    All documents and definitive proxy or information statements filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing

     


     

    of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission. Unless expressly incorporated into this Registration Statement, a report deemed to be furnished but not filed on Form 8-K prior or subsequent to the date hereof shall not be incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement.

    Item 5. Interests of Named Experts and Counsel

    As of the date of this registration statement, individuals and entities associated with Fenwick & West LLP beneficially own an aggregate of 4,380 shares of the Registrant’s common stock.

    Item 8. Exhibits

    The following exhibits are filed herewith:

    Exhibit

    Incorporated by Reference

    Number

    Exhibit Description

    Form

    File No.

    Exhibit

    Filing Date

    Filed Herewith

    3.1

    Restated Certificate of Incorporation of the Registrant

    10-Q

    001-42279

    3.1

    11/7/2024

    3.2

    Amended and Restated Bylaws of the Registrant

    10-Q

    001-42279

    3.2

    11/7/2024

    4.1

    Form of Common Stock Certificate

    S-1

    333-281901

    4.1

    09/03/2024

    5.1

    Opinion of Fenwick & West LLP

    X

    23.1

    Consent of Fenwick & West LLP (contained in Exhibit 5.1)

    X

    23.2

    Consent of KPMG LLP, Independent Registered Public Accounting Firm

    X

    24.1

    Power of Attorney (included on the signature page to this Registration Statement)

    X

    99.1

    2024 Equity Incentive Plan, and forms of award agreements thereunder

    10-K

    001-42279

    10.2

    03/20/2025

    99.2

    2024 Employee Stock Purchase Plan, and forms of award agreements thereunder

    S-1/A

    333-281901

    10.4

    09/18/2024

    107

    Filing Fee Table

    X

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Emeryville, State of California, on this 24th day of March, 2026.

    BIOAGE LABS, INC.

    By:

     

    /s/ Kristen Fortney, Ph.D.

     

     

    Kristen Fortney, Ph.D.

     

     

    Chief Executive Officer and President

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Kristen Fortney, Ph.D. and Dov Goldstein, M.D., and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons on behalf of the Registrant in the capacities and on the date indicated.

    Name

    Title

    Date

    /s/ Kristen Fortney

    Chief Executive Officer, President and Director

    March 24, 2026

    Kristen Fortney, Ph.D.

    (Principal Executive Officer)

     

     

     

     

    /s/ Dov Goldstein

    Chief Financial Officer

    March 24, 2026

    Dov Goldstein, M.D.

    (Principal Financial Officer)

     

     

     

     

    /s/ Shane Barton

    Senior Vice President of Finance

    March 24, 2026

    Shane Barton

    (Principal Accounting Officer)

     

     

     

     

    /s/ Jean-Pierre Garnier

    Chair of the Board of Directors

    March 24, 2026

    Jean-Pierre Garnier, Ph.D.

     

     

     

     

     

    /s/ Michael Davidson

    Director

    March 24, 2026

    Michael Davidson, M.D.

     

     

     

     

     

    /s/ Patrick Enright

    Director

    March 24, 2026

    Patrick Enright

     

     

     

     

     

    /s/ James Healy

    Director

    March 24, 2026

    James Healy, M.D., Ph.D.

     

     

     

     

     

    /s/ Rekha Hemrajani

    Director

    March 24, 2026

    Rekha Hemrajani

     

     

     


     

    Name

    Title

    Date

    /s/ Eric Morgen

    Director

    March 24, 2026

    Eric Morgen, M.D.

     

     

     

     

     

    /s/ Vijay Pande

    Director

    March 24, 2026

    Vijay Pande, Ph.D.

     

     

     


    Get the next $BIOA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIOA

    DatePrice TargetRatingAnalyst
    2/25/2026$60.00Outperform
    Oppenheimer
    2/18/2026$62.00Hold → Buy
    Jefferies
    1/27/2026$73.00Overweight
    Piper Sandler
    12/5/2025$12.00Underweight → Equal-Weight
    Morgan Stanley
    10/22/2025$10.00Neutral → Buy
    Citigroup
    2/28/2025Mkt Perform
    William Blair
    12/10/2024$40.00 → $5.00Overweight → Underweight
    Morgan Stanley
    12/9/2024$42.00 → $7.00Buy → Hold
    Jefferies
    More analyst ratings

    $BIOA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025

    Positive interim Phase 1 data for BGE-102, a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor, demonstrating potential best-in-class reductions in inflammatory biomarkers of cardiovascular risk; Phase 2a proof-of-concept trial planned to initiate in 1H 2026 Indication expansion for BGE-102 into ophthalmology; Phase 1b/2a proof-of-concept trial in diabetic macular edema planned to initiate mid-2026 Completed upsized follow-on public offering of $132.3 million with full exercise of the underwriters' overallotment option in February 2026 EMERYVILLE, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a cl

    3/24/26 9:00:00 AM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress

    STOCKHOLM, March 23, 2026 /PRNewswire/ -- BioArctic's AB (publ) (NASDAQ:BIOA) partner Eisai presented new data at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD™), held in Copenhagen, Denmark March 17-21. BioArctic also held an oral presentation on lecanemab and a poster presentation relating to exidavnemab.   Eisai presented new real-world findings from an analysis of long-term treatment persistence among early Alzheimer's disease patients in the United States receiving intravenous (IV) lecanemab. Based on data from the PurpleLab®[1] claims database, the analysis showed that most patients continued lecanemab therapy after

    3/23/26 3:50:00 AM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

    EMERYVILLE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference taking place February 25-26, 2026. Kristen Fortney, PhD, CEO and co-founder, is scheduled to participate in a fireside chat on Thursday, February 26 from 10:40 AM to 11:05 AM ET. Fortney and Dov Goldstein, MD, CFO, will participate in one-on-one meetings. To access the live webcast of the presentation, register here. Replay

    2/19/26 4:30:00 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Rubin Paul D exercised 7,433 shares at a strike of $4.77 and sold $150,890 worth of shares (7,433 units at $20.30) (SEC Form 4)

    4 - BioAge Labs, Inc. (0001709941) (Issuer)

    3/3/26 4:46:45 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Goldstein Dov A Md exercised 3,542 shares at a strike of $4.38, increasing direct ownership by 12% to 33,033 units (SEC Form 4)

    4 - BioAge Labs, Inc. (0001709941) (Issuer)

    3/3/26 4:44:53 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Medical Officer Rubin Paul D

    4 - BioAge Labs, Inc. (0001709941) (Issuer)

    2/19/26 4:42:42 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOA
    SEC Filings

    View All

    SEC Form S-3ASR filed by BioAge Labs Inc.

    S-3ASR - BioAge Labs, Inc. (0001709941) (Filer)

    3/24/26 4:22:28 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by BioAge Labs Inc.

    S-8 - BioAge Labs, Inc. (0001709941) (Filer)

    3/24/26 4:07:46 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by BioAge Labs Inc.

    10-K - BioAge Labs, Inc. (0001709941) (Filer)

    3/24/26 9:15:30 AM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Hemrajani Rekha bought $54,000 worth of shares (3,000 units at $18.00) (SEC Form 4)

    4/A - BioAge Labs, Inc. (0001709941) (Issuer)

    3/10/25 4:11:28 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Principal Accounting Officer Barton Shane bought $47,376 worth of shares (2,632 units at $18.00) (SEC Form 4)

    4 - BioAge Labs, Inc. (0001709941) (Issuer)

    3/10/25 4:10:37 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Pande Vijay Satyanand bought $4,329,019 worth of shares (219,195 units at $19.75) (SEC Form 4)

    4 - BioAge Labs, Inc. (0001709941) (Issuer)

    10/3/24 7:19:49 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on BioAge Labs with a new price target

    Oppenheimer initiated coverage of BioAge Labs with a rating of Outperform and set a new price target of $60.00

    2/25/26 7:48:37 AM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioAge Labs upgraded by Jefferies with a new price target

    Jefferies upgraded BioAge Labs from Hold to Buy and set a new price target of $62.00

    2/18/26 7:49:56 AM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on BioAge Labs with a new price target

    Piper Sandler initiated coverage of BioAge Labs with a rating of Overweight and set a new price target of $73.00

    1/27/26 8:43:35 AM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by BioAge Labs Inc.

    SC 13G - BioAge Labs, Inc. (0001709941) (Subject)

    11/14/24 4:15:56 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by BioAge Labs Inc.

    SC 13G - BioAge Labs, Inc. (0001709941) (Subject)

    11/12/24 4:15:53 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by BioAge Labs Inc.

    SC 13D - BioAge Labs, Inc. (0001709941) (Subject)

    10/4/24 8:21:35 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care